Marshall Wace, LLP Ideaya Biosciences, Inc. Transaction History

Marshall Wace, LLP

$72.2 Billion
Q2 2024

A detailed history of Marshall Wace, LLP transactions in Ideaya Biosciences, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 98,811 shares of IDYA stock, worth $3.13 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

98,811

Previous 110,351 10.46%

Holding current value

$3.13 Million

Previous $4.84 Million 28.36%

% of portfolio

0.0%

Previous 0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$34.37 - $43.46 $396,629 - $501,528	-11,540 Reduced 10.46%	98,811 $3.47 Million
Q1 2024 May 15, 2024	BUY	$34.2 - $47.13 $3.77 Million - $5.2 Million	110,351 New	110,351 $4.84 Million
Q1 2023 May 15, 2023	BUY	$13.49 - $18.72 $376,411 - $522,344	27,903 New	27,903 $383,000
Q3 2022 Nov 14, 2022	BUY	$9.24 - $15.79 $102,148 - $174,558	11,055 New	11,055 $166,000
Q2 2022 Aug 15, 2022	SELL	$8.28 - $13.88 $1.38 Million - $2.32 Million	-166,805 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$11.18 - $24.02 $1.83 Million - $3.93 Million	163,482 Added 4919.71%	166,805 $1.87 Million
Q4 2021 Feb 14, 2022	BUY	$20.95 - $26.88 $69,616 - $89,322	3,323 New	3,323 $79,000
Q2 2021 Aug 13, 2021	SELL	$17.76 - $24.83 $180,441 - $252,272	-10,160 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$13.48 - $23.77 $136,956 - $241,503	10,160 New	10,160 $239,000
Q3 2020 Nov 16, 2020	SELL	$11.22 - $14.46 $305,498 - $393,716	-27,228 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$3.59 - $18.57 $97,748 - $505,623	27,228 New	27,228 $388,000

Others Institutions Holding IDYA

# of Institutions

206

Shares Held

73.6M

Call Options Held

21.5K

Put Options Held

20.3K

View Full List

About IDEAYA Biosciences, Inc.

Ticker IDYA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,067,700
Market Cap $1.52B
Description
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinica...

More about IDYA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Account

Marshall Wace, LLP Ideaya Biosciences, Inc. Transaction History